

Azerbaijan

Population 2016

9.7 million

| Estimates of TB burden*, 2016 | Number (thousands) | Rate (per 100 000 population) |
|-------------------------------|--------------------|-------------------------------|
| Mortality (excludes HIV+TB) | 0.62 (0.61–0.63) | 6.4 (6.3–6.5) |
| Mortality (HIV+TB only) | 0.028 (0.02–0.036) | 0.28 (0.2–0.37) |
| Incidence (includes HIV+TB) | 6.4 (4.9–8.2) | 66 (51–84) |
| Incidence (HIV+TB only) | 0.13 (0.083–0.18) | 1.3 (0.86–1.9) |
| Incidence (MDR/RR-TB)** | 2.4 (2–2.9) | 25 (20–30) |

| Estimated TB incidence by age and sex (thousands)*, 2016 | | | |
|--|------------------|---------------|---------------|
| | 0-14 years | > 14 years | Total |
| Females | 0.35 (0.27–0.44) | 1.8 (1.4–2.3) | 2.2 (1.6–2.7) |
| Males | 0.4 (0.3–0.5) | 3.9 (2.9–4.9) | 4.3 (3.2–5.4) |
| Total | 0.76 (0.57–0.94) | 5.7 (4.3–7.1) | 6.4 (4.9–8.2) |

| TB case notifications, 2016 | |
|--|-------|
| Total cases notified | 6 707 |
| Total new and relapse | 5 159 |
| - % tested with rapid diagnostics at time of diagnosis | 39% |
| - % with known HIV status | 70% |
| - % pulmonary | 80% |
| - % bacteriologically confirmed among pulmonary | 61% |

| Universal health coverage and social protection | |
|--|-----------------|
| TB treatment coverage (notified/estimated incidence), 2016 | 80% (63–100) |
| TB patients facing catastrophic total costs | |
| TB case fatality ratio (estimated mortality/estimated incidence), 2016 | 0.1 (0.08–0.13) |

| TB/HIV care in new and relapse TB patients, 2016 | | |
|---|--------|-----|
| | Number | (%) |
| Patients with known HIV-status who are HIV-positive | 99 | 2% |
| - on antiretroviral therapy | 78 | 79% |

| Drug-resistant TB care, 2016 | | | |
|---|-------------|----------------------------|---------------------|
| | New cases | Previously treated cases | Total number*** |
| Estimated MDR/RR-TB cases among notified pulmonary TB cases | | | 1 500 (1 400–1 600) |
| Estimated % of TB cases with MDR/RR-TB | 13% (10–16) | 39% (37–42) | |
| % notified tested for rifampicin resistance | 31% | 61% | 2 955 |
| MDR/RR-TB cases tested for resistance to second-line drugs | | | 589 |
| Laboratory-confirmed cases | | MDR/RR-TB: 925, XDR-TB: 77 | |
| Patients started on treatment **** | | MDR/RR-TB: 798, XDR-TB: 0 | |

| Treatment success rate and cohort size | | |
|--|---------|--------|
| | Success | Cohort |
| New cases registered in 2015 | 83% | 1 475 |
| Previously treated cases registered in 2015 | 73% | 2 738 |
| HIV-positive TB cases registered in 2015 | | |
| MDR/RR-TB cases started on second-line treatment in 2014 | 59% | 745 |
| XDR-TB cases started on second-line treatment in 2014 | 23% | 69 |

| TB preventive treatment, 2016 | |
|---|--------------|
| % of HIV-positive people (newly enrolled in care) on preventive treatment | 60% |
| % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment | 86% (63–100) |

| TB financing, 2017 | |
|------------------------------------|--|
| National TB budget (US\$ millions) | |

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New cases
— Previously treated cases
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

